Study sample characteristics
| Study site | Institut Pasteur (Paris, France) | Queen’s Medical Centre (Nottingham, UK) | Lancet Laboratories (Johannesburg, South Africa) |
| Gold standard assay | Abbott RealTime | Abbott RealTime | Abbott RealTime |
| HCV-positive cases (n) | 221 | 201 | 118 |
| Controls (n) | 190 | 313 | 12 |
| Condition of sample storage | Frozen | Frozen (201 cases and 313 controls) Fresh (51 cases and 49 controls) | Frozen |
| Type of sample | Plasma | Plasma (124 cases and 234 controls) Serum (77 cases and 79 controls) | Plasma/serum |
| Anticoagulant | Na-heparin | EDTA and SST tubes | Information not recorded |
| Genotype distribution | g1a and g1b (88%) and g4 (12%) | g1a and g1b (62%), g3 (33%), g2 (2.2%), g4 (2.2%), g5 (1.1%) | Data available for 98% of the cases: g1a (40.5%), g4 (27.5%), g1b (15.5%), g3 (6%), g2 (5%), g5 (5%). |
| No of daily controls | 1 positive and 3 negative | 4 positive and 4 negative | None |
| No of operators | 2 | 3 | 4 |
| No of Genedrive units | 4 | 8 | 3 |
HCV, hepatitis C virus; SST, serum-separating tube.